Application | Comment | Organism |
---|---|---|
medicine | major clinical trials with DPP-IV inhibitors as monotherapy and as add-on therapy in patients with type 2 diabetes. The magnitude of HbA1c reduction with DPP-IV inhibitors depends upon the pretreatment HbA1c values, but there seems to be no change in body weight, and very low rates of hypoglycaemia and gastrointestinal disturbance with these agents. DPP-IV inhibitors represent a major class of oral antidiabetic drug and their metabolic profile offers a number of unique clinical advantages for the management of type 2 diabetes | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
sitagliptin | highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism | Homo sapiens | |
vildagliptin | highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Synonyms | Comment | Organism |
---|---|---|
dipeptidyl peptidase-IV | - |
Homo sapiens |
DPP-IV | - |
Homo sapiens |